Abiomed (ABMD) Tops Q3 EPS by 16c; Raises Low End of FY Revenues Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Join SI Premium – FREE
Abiomed (NASDAQ: ABMD) reported Q3 EPS of $1.13, $0.16 better than the analyst estimate of $0.97. Revenue for the quarter came in at $261 million versus the consensus estimate of $253.8 million.
GUIDANCE:
Abiomed sees FY2022 revenue of $1.025-1.03 billion, versus the consensus of $1.02 billion.
For earnings history and earnings-related data on Abiomed (ABMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- ACRES Commercial Realty (ACR) Misses Q3 EPS by 526c
- CrossAmerica Partners (CAPL) Misses Q3 EPS by 8c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
